Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib and S-1 in Advanced Pancreatic Cancer
NCT03662035Phase 2Unknown
- Sponsor
- Changzhou Second People's Hospital
- Start
- Sep 2018
- Primary completion
- Mar 2020
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of Rivoceranib in pancreatic cancer (PC), sponsored by Changzhou Second People's Hospital. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03662035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03662035.